Drugs / F-18 tetrafluoroborate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03456908 | Mar 2018 → Dec 2019 | female reproductive organ cancer, plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F-18 tetrafluoroborate | “The goal of this proposal is to perform first-in-man evaluation of the imaging probe F-18 tetrafluoroborate (BF4) as a PET imaging biomarker for expression of the human...” NCT03456908 ↗ |
| Known as | BF4 | “The goal of this proposal is to perform first-in-man evaluation of the imaging probe F-18 tetrafluoroborate (BF4) as a PET imaging biomarker for expression of the human...” NCT03456908 ↗ |
| Modality | Diagnostic / imaging agent | “imaging probe F-18 tetrafluoroborate (BF4) as a PET imaging biomarker” NCT03456908 ↗ |
| Route | Other | “Infusion of F-18 TFB” NCT03456908 ↗ |